MDRNA, Inc. Earnings Conference Call (Q3 2009)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Nov 12 Calls Today's Calls

Call Details MDRNA, Inc. Earnings Conference Call (Q3 2009) Thu, Nov 12, 2009, 4:30 pm Eastern Listen to the archived event audio About MDRNA, Inc. (NasdaqGM:MRNA) MDRNA, Inc. operates as a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). The company seeks to improve human health by combining RNAi-based compounds and proprietary peptide- and liposomal-based drug delivery technologies to provide therapeutic options. MDRNA's multi-disciplinary portfolio of capabilities includes molecular biology, cellular biology, formulation expertise, peptide and alkylated amino acid chemistry, pharmacology, toxicology, and bioinformatics. The company is applying this expertise to a single, integrated drug discovery platform that would be the engine for its clinical pipeline and a versatile platform for establishing therapeutic partnerships. MDRNA is also building on new technologies, such as UsiRNAs that incorporate the non-nucleotide moiety Unlocked Nucleobase Analog (UNA) within the siRNA molecule, that might lead to safer and more effective RNAi-based therapeutics. The company combines expertise in siRNA science with proven delivery platforms and a growing IP portfolio, positioning MDRNA as an RNAi therapeutics company and a value-added collaborator for its research partners. It was formerly known as Nastech Pharmaceutical Company Inc. and changed its name to MDRNA, Inc. The company was founded in 1983 and is headquartered in Bothell, Washington. More Info: Quote | Profile | Reports | Research | Insider | Financials | Analyst Ratings